Dalteparin sodium treatment during resuscitation inhibits hemorrhagic shock-induced leukocyte rolling and adhesion in the mesenteric microcirculation

Journal of Trauma

Volumn 52, Issue 6, 2002, Pages 1062-1070

  Balogh, Zsolt ^a   Wolfárd, Antal ^a   Szalay, László ^b   Orosz, Edit ^b   Simonka, János Aurél ^a   Boros, Mihály ^b  

^a Department of Traumatology ^*  (Hungary)

^b UNIVERSITY OF SZEGED   (Hungary)

Author keywords

Adhesion; Hemorrhagic shock; Heparin; Intravital video microscopy; Ischemia reperfusion; Leukocyte

Indexed keywords

DALTEPARIN; LOW MOLECULAR WEIGHT HEPARIN; RINGER LACTATE SOLUTION;

ANIMAL EXPERIMENT; ARTICLE; CELL INTERACTION; CONTROLLED STUDY; ENDOTHELIUM CELL; EXTRAVASATION; HEMORRHAGIC SHOCK; ISCHEMIA; LEUKOCYTE ADHERENCE; MEAN ARTERIAL PRESSURE; MESENTERY BLOOD FLOW; MICROCIRCULATION; NONHUMAN; PRIORITY JOURNAL; REPERFUSION; RESUSCITATION;

ANIMALS; ANTICOAGULANTS; BLOOD PRESSURE; CELL ADHESION MOLECULES; DALTEPARIN; DOGS; HEPARIN, LOW-MOLECULAR-WEIGHT; RESUSCITATION; SHOCK, HEMORRHAGIC; SPLANCHNIC CIRCULATION;

EID: 0036087534     PISSN: 00225282     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005373-200206000-00007     Document Type: Article

References (22)

1. Committee on Trauma Research, Commission on Life Sciences, National Research Council and the Institute of Medicine. Injury in America. Washington DC; National Academy Press; 1995.
2. Sauaia A, Moore FA, Moore EE, et al. Epidemiology of trauma deaths; a reassessment. J Trauma. 1995; 38; 185-193.
3. Moore FA, Moore EE. Evolving concept in the pathogenesis of postinjury multiple organ failure. Surg Clin North Am. 1995; 75; 257-277.
4. Patrick DA, Moore FA, Moore EE, Barnett CC Jr, Silliman CC. Neutrophil priming and activation in the pathogenesis of postinjury multiple organ failure. New Horiz. 1996; 4; 194-210.
5. Hassoun HT, Kone BC, Mercer DW, Moody FG, Weisbrodt NW, Moore FA. Post-injury multiple organ failure; the role of the gut. Shock. 2001; 15; 1-10.
6. Suzuki M, Inaunen W, Kvietys PR, et al. Superoxide mediates reperfusion-induced injury leukocyte-endothelial cell interactions. Am J Physiol. 1989; 257; 1667-1673.
7. Kansas GS. Selectins and their ligands; current concepts and controversies. Blood. 1996; 88; 3258-3287.
8. Koenig A, Norgard-Sumnicht K, Linhardt R, Varki A. Differential interactions of heparin and heparan sulfate glycosaminoglycans with the selectins; implications for the use of unfractionated and low molecular weight heparins as therapeutic agents. J Clin Invest. 1998; 101; 877-889.
9. Ley K, Cerrito M, Arfors KE. Sulfated polysaccharides inhibit leukocyte rolling in rabbit mesentery venules. Am J Physiol. 1991; 260; H1667-H1673.
10. Hartl P, Brucke P, Dienstl E, Vinazzer H. Prophylaxis in general surgery; comparison between standard heparin and Fragmin. Thromb Res. 1990; 57; 577-584.
11. Kakkar VV, Cohen AT, Edmondson RA, et al. Low molecular weight versus standard heparin for prevention of venous thromboembolism after major abdominal surgery. Lancet. 1993; 341; 259-265.
12. Pineo GF, Hull RD. Unfractionated and low-molecular-weight-heparin; comparisons and current recommendations. Med Clin North Am. 1998; 82; 587-599.
13. Wolf H. Low-molecular-weight heparin. Med Clin North Am. 1994; 78; 733-743.
14. Holmer E, Soderberg K, Bergqvist D, et al. Heparin and its low molecular weight derivatives; anticoagulant and antithrombotic properties. Haemostasis. 1986; 16 (suppl 2); 1-7.
15. Bergqvist A. Thromboprophylactic effect of low molecular weight heparin started in the evening before general abdominal surgery; a comparison with low-dose heparin. Semin Thromb Hemost. 1990; 16; 19-24.
16. Baue AE, Durham R, Faist E. Systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), multiple organ failure (MOF); are we winning the battle? Shock. 1998; 10; 79-89.
17. Vincent JL. Prevention and therapy of multiple organ failure. World J Surg. 1996; 20; 465-470.
18. Baue AE, Durham RM, Mazuski JE. Clinical trials of new and novel therapeutic agents. World J Surg. 1996; 20; 493-498.
19. Xie X, Rivier AS, Zakrzewicz A, et al. Inhibition of selectin-mediated cell adhesion and prevention of acute inflammation by nonanticoagulant sulfated saccharides. J Biol Chem. 2000; 275; 34818-34825.
20. Dunn CJ, Sorkin EM. Dalteparin sodium; a review of its pharmacology and clinical use in the prevention and treatment of thromboembolic disorders. Drugs. 1996; 52; 276-305.
21. Bratt G, Thornebohm E, Widlund L, et al. Low molecular weight heparin (Kabi 2165, Fragmin); pharmacokinetics after intravenous and subcutaneous administration in human volunteers. Thromb Res. 1986; 42; 613-620.
22. Dunn CJ, Jarvis B. Dalteparin; an update of its pharmacological properties and clinical efficacy in the prophylaxis and treatment of thromboembolic disease. Drugs. 2000; 60; 203-237.